KR20190139327A - 초고순도 테트라하이드로카나비놀-11-오익산 - Google Patents

초고순도 테트라하이드로카나비놀-11-오익산 Download PDF

Info

Publication number
KR20190139327A
KR20190139327A KR1020197036267A KR20197036267A KR20190139327A KR 20190139327 A KR20190139327 A KR 20190139327A KR 1020197036267 A KR1020197036267 A KR 1020197036267A KR 20197036267 A KR20197036267 A KR 20197036267A KR 20190139327 A KR20190139327 A KR 20190139327A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
acid
azulemic
receptor
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197036267A
Other languages
English (en)
Korean (ko)
Inventor
마크 테퍼
Original Assignee
코버스 파마수티컬스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코버스 파마수티컬스, 아이엔씨. filed Critical 코버스 파마수티컬스, 아이엔씨.
Publication of KR20190139327A publication Critical patent/KR20190139327A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197036267A 2013-02-12 2014-02-12 초고순도 테트라하이드로카나비놀-11-오익산 Ceased KR20190139327A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763630P 2013-02-12 2013-02-12
US61/763,630 2013-02-12
US201361837743P 2013-06-21 2013-06-21
US61/837,743 2013-06-21
PCT/US2014/016050 WO2014127016A2 (en) 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157024773A Division KR20160002709A (ko) 2013-02-12 2014-02-12 초고순도 테트라하이드로카나비놀-11-오익산

Publications (1)

Publication Number Publication Date
KR20190139327A true KR20190139327A (ko) 2019-12-17

Family

ID=51354671

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197036267A Ceased KR20190139327A (ko) 2013-02-12 2014-02-12 초고순도 테트라하이드로카나비놀-11-오익산
KR1020157024773A Ceased KR20160002709A (ko) 2013-02-12 2014-02-12 초고순도 테트라하이드로카나비놀-11-오익산

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157024773A Ceased KR20160002709A (ko) 2013-02-12 2014-02-12 초고순도 테트라하이드로카나비놀-11-오익산

Country Status (9)

Country Link
US (8) US20150141501A1 (https=)
EP (2) EP3851101A1 (https=)
JP (3) JP6689078B2 (https=)
KR (2) KR20190139327A (https=)
CN (2) CN105228613A (https=)
AU (2) AU2014216440B2 (https=)
BR (1) BR112015019180A8 (https=)
CA (1) CA2900982C (https=)
WO (1) WO2014127016A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015019180A8 (pt) 2013-02-12 2018-01-30 Corbus Pharmaceuticals Inc ácidos tetrahidrocanabinol-11-óicos ultrapuros
JP2019515927A (ja) * 2016-04-29 2019-06-13 コーバス ファーマシューティカルズ インク． 感染症の処置のための方法
BR112018077541A2 (pt) * 2016-07-11 2019-04-30 Intec Pharma Ltd. formulações orais gastrorretentivas e usos das mesmas
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
AU2019278992A1 (en) * 2018-05-31 2020-12-17 Corbus Pharmaceuticals Inc. Cannabinoids and uses thereof
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
US20200121614A1 (en) * 2018-10-18 2020-04-23 Bluegrass Farmacueticals, LLC Cannabinoid-infused transparent hydrogel skin patch
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients
US20230339880A1 (en) 2019-10-11 2023-10-26 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof
WO2022020421A1 (en) * 2020-07-21 2022-01-27 Np Pharma Holdings, Llc Cannabinoid compositions and methods for treating joint pain and inflammation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US8586767B2 (en) 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6974835B2 (en) 2000-05-17 2005-12-13 Indevus Pharmaceuticals, Inc. Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
WO2002070506A2 (en) * 2001-03-07 2002-09-12 Websar Innovations Inc. Conversion of cbd to δ8-thc and δ9-thc
CA2507815A1 (en) * 2002-12-04 2004-06-17 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
IL153277A0 (en) * 2002-12-04 2003-07-06 Pharmos Corp High enantiomeric purity dexanabinol for pharmaceutical compositions
WO2004054554A1 (en) 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
WO2004100893A2 (en) 2003-05-12 2004-11-25 Indevus Pharmaceuticals, Inc. Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
US20050009903A1 (en) * 2003-06-10 2005-01-13 Martin Billy R. CB2-selective cannabinoid analogues
AU2006240490A1 (en) 2005-04-21 2006-11-02 Paladin Labs (Barbados) Inc. Process for the preparation of ultrapure 4-methylprazole
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070037873A1 (en) 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US20070060639A1 (en) 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
US20070104741A1 (en) 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
US20080054300A1 (en) * 2006-06-30 2008-03-06 Philip Gene Nikkel Body contact structure and method for the reduction of drain lag and gate lag in field effect transistors
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8044071B2 (en) 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
WO2009158499A2 (en) 2008-06-25 2009-12-30 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
WO2012048045A1 (en) 2010-10-05 2012-04-12 Jb Therapeutics, Inc. Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
BR112015019180A8 (pt) * 2013-02-12 2018-01-30 Corbus Pharmaceuticals Inc ácidos tetrahidrocanabinol-11-óicos ultrapuros
US20150328198A1 (en) 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Also Published As

Publication number Publication date
US11052066B2 (en) 2021-07-06
CA2900982C (en) 2021-06-01
US10154986B2 (en) 2018-12-18
AU2014216440A1 (en) 2015-08-20
EP3851101A1 (en) 2021-07-21
CN105228613A (zh) 2016-01-06
US20190091200A1 (en) 2019-03-28
CN110946854A (zh) 2020-04-03
US10085964B2 (en) 2018-10-02
WO2014127016A2 (en) 2014-08-21
US9820964B2 (en) 2017-11-21
JP2019031505A (ja) 2019-02-28
BR112015019180A2 (pt) 2017-07-18
EP2956133A4 (en) 2016-12-21
JP2016510340A (ja) 2016-04-07
CA2900982A1 (en) 2014-08-21
US20220117931A1 (en) 2022-04-21
BR112015019180A8 (pt) 2018-01-30
US20180177757A1 (en) 2018-06-28
AU2018258159B2 (en) 2020-01-02
US20170071898A1 (en) 2017-03-16
US20170071900A1 (en) 2017-03-16
JP6689078B2 (ja) 2020-04-28
KR20160002709A (ko) 2016-01-08
WO2014127016A3 (en) 2015-11-26
US20200093784A1 (en) 2020-03-26
AU2014216440B2 (en) 2018-08-09
US20150141501A1 (en) 2015-05-21
JP2021185166A (ja) 2021-12-09
EP2956133A2 (en) 2015-12-23
US20170071899A1 (en) 2017-03-16
AU2018258159A1 (en) 2018-11-22
US10369131B2 (en) 2019-08-06
US9801849B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
US11052066B2 (en) Ultrapure tetrahydrocannabinol-11-oic acids
EP3525784B1 (en) Sparsentan for use in the treatment of alport syndrome
CN114746430B (zh) 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物
US10329243B2 (en) Biphenyl derivative and uses thereof
WO2018071679A1 (en) N-acylethanolamide derivatives and uses thereof
US20240358681A1 (en) Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
HK40026965A (en) Ultrapure tetrahydrocannabinol-11-oic acids
CN104873482B (zh) 一种抗慢性心力衰竭的药物组合物
JP2022530461A (ja) アテローム性動脈硬化を治療するための医薬品の製造における化合物の使用
EP2588462A1 (en) Metronidazole esters for treating rosacea
WO2026077289A1 (zh) 一种天然衍生物在制备治疗心肌病和/或心肌纤维化药物中的应用
CN107417669A (zh) 3-(1h-吲唑)-四氢嘧啶-2-酮类化合物、其制备方法及其用途

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191206

Application number text: 1020157024773

Filing date: 20150910

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200102

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200120

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210927

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200120

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I